Who owns Pieris Pharmaceuticals?
- Ticker: PIRS
- CUSIP Number: 720795103
Tip: Access positions for across all investors
Analyze quarterly positions in Pieris Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Pieris Pharmaceuticals stock
Who bought or sold Pieris Pharmaceuticals this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BVF | 21M | $3.8M | 0% | Mar 2024 |
|
| Lynx1 Capital Management | 8.8M | $1.6M | -10% | Mar 2024 |
|
| BlackRock | 1.0M | $190k | 0% | Mar 2024 |
|
| Citadel Advisors | 967k | $179k | -23% | Mar 2024 |
|
| Acadian Asset Management | 962k | $175k | 0% | Mar 2024 |
|
| Vanguard Group | 907k | $166k | 0% | Mar 2024 |
|
| Geode Capital Management | 773k | $142k | 1% | Mar 2024 |
|
| CM Management | 575k | $105k | -23% | Mar 2024 |
|
| Northern Trust | 244k | $45k | 77% | Mar 2024 |
|
| Millennium Management | 212k | $39k | 27% | Mar 2024 |
|
| Squarepoint Ops | 146k | $27k | 100% | Mar 2024 |
|
| Summit Trail Advisors | 140k | $26k | 100% | Mar 2024 |
|
| Citigroup | 89k | $16k | 0% | Mar 2024 |
|
| Two Sigma Securities | 58k | $11k | 278% | Mar 2024 |
|
| UBS Group | 52k | $9.5k | 728% | Mar 2024 |
|
| Tower Research Capital | 43k | $7.8k | 38% | Mar 2024 |
|
| Two Sigma Advisers | 34k | $6.2k | -2% | Mar 2024 |
|
| Raymond James & Associates | 30k | $5.5k | 0% | Mar 2024 |
|
| NJ State Employees Deferred Compensation Plan | 30k | $5.5k | 0% | Mar 2024 |
|
| Group One Trading | 26k | $4.7k | 282% | Mar 2024 |
|
| Goldman Sachs Group | 23k | $332k | 0% | Mar 2024 |
|
| XTX Topco | 21k | $3.8k | 100% | Mar 2024 |
|
| Commerce Bank N A | 20k | $3.7k | 0% | Mar 2024 |
|
| Kestra Advisory Services | 18k | $3.2k | 100% | Dec 2023 |
|
| National Asset Management | 17k | $5.1k | 100% | Mar 2024 |
|
| Hudson Valley Investment Advisors | 14k | $2.6k | 0% | Mar 2024 |
|
| HPM Partners | 10k | $1.9k | 0% | Mar 2024 |
|
| Us Bancorp | 10k | $1.9k | 0% | Mar 2024 |
|
| Morgan Stanley | 6.9k | $1.3k | -16% | Mar 2024 |
|
| Bank of America Corporation | 6.1k | $1.1k | 4138% | Mar 2024 |
|
| Wells Fargo & Company | 5.6k | $1.0k | 17% | Mar 2024 |
|
| Barclays | 5.0k | $1.0k | 0% | Mar 2024 |
|
| Cutler | 4.5k | $0 | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 2.0k | $364.583700 | 1% | Mar 2024 |
|
| Advisor Group Holdings | 516.00 | $94.995600 | 0% | Mar 2024 |
|
| Hanson McClain Advisors | 350.00 | $64.995000 | 0% | Mar 2024 |
|
| Royal Bank of Canada | 272.00 | $0 | -52% | Mar 2024 |
|
Who sold out of Pieris Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Virtu Financial | Dec 2023 | 90k | $16k |
| Two Sigma Investments | Dec 2023 | 41k | $7.4k |
| Bank of New York Mellon | Dec 2023 | 40k | $7.3k |
| NorthStar Asset Management | Dec 2023 | 39k | $7.1k |
| Baader Bank | Dec 2023 | 20k | $2.7k |
| 1620 Investment Advisors | Dec 2023 | 4.4k | $318k |
| Rhumbline Advisers | Dec 2023 | 1.9k | $339.052200 |